Anavex Life Sciences Corp (AVXL)
R&D Expense Growth
-1.15%
Quarterly · Period ending:
AVXL R&D Expense Growth
Latest reported-1.15%period ending
Latest reported-1.15%period ending
AVXL Quarterly R&D Growth (QoQ) (0.00% → -1.15%)
Latest values, visible window
High-resolution chart · PNG
AVXL r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| -1.145% | |
| -9.9656% | |
| -36.1667% | |
| -26.7597% | |
| 0.6773% | |
| -5.3035% | |
| -9.5976% | |
| -2.1675% | |
| 21.3999% | |
| 12.0336% | |
| -13.6834% | |
| -2.1624% | |
| -2.5954% | |
| -12.5135% | |
| 6.0234% | |
| 22.734% | |
| 7.7712% | |
| -0.599% | |
| -7.6428% | |
| 4.5541% | |
| 33.384% | |
| -15.2% | |
| 29.8221% | |
| -9.2207% | |
| 11.1011% | |
| -4.6564% | |
| 34.7653% | |
| -18.1913% | |
| -5.2698% | |
| 6.4174% | |
| 29.6035% | |
| 47.031% | |
| -7.6236% | |
| 20.4398% | |
| -29.7695% | |
| 66.7793% | |
| -7.7281% | |
| 22.0536% | |
| -52.9258% | |
| 274.4215% | |
| 6.2624% | |
| -6.2862% | |
| 55.8839% | |
| -6.6243% | |
| 96.3576% | |
| 27.7822% | |
| -7.3894% | |
| 29.8221% | |
| 124.3001% | |
| 2,180.9266% | |
| -94.6742% | |
| 149.2581% | |
| 6,868.0357% | |
| -99.5591% | |
| 12.4348% | |
| -71.328% | |
| -8.2969% | |
| -74.9841% | |
| 190.1998% | |
| -23.9334% | |
| 6.5361% | |
| 46.8443% | |
| -54.3178% | |
| 77.5369% | |
| -24.8217% | |
| 285.669% | |
| -80.2568% | |
| 135.0643% | |
| 38.5649% | |
| 15.753% | |
| -63.7869% | |
| 216.0487% | |
| 11.033% | |
| -24.2534% | |
| -66.9929% | |
| 2,138.1348% | |
| 56.4147% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |